Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Condition:   Chronic Graft Versus Host Disease Interventions:   Drug: Belumosudil;   Drug: Rituximab Sponsors:   Northside Hospital, Inc.;   Sanofi Not yet recruiting

Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials